Business
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update.
About this update from Azitra Inc
[{"type":"text","content":"BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update.","length":350,"tagName":"p"},{"type":"image","alt":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","displaySize":"","headline":null,"caption":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":199,"url":"https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ADn6KpXSrfB9stFJaBf9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MzmJZI_I8X_gtWHAe3fWAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMxODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199}},"href":"https://mma.prnewswire.com/media/2555910/Azitra_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Q1 2026 and Recent Business Highlights","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced the addition of MD Anderson Cancer Center as a clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated skin rash.","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched innovative protein and peptide programs for the cosmetic and cosmeceutical markets leveraging proprietary filaggrin technologies.","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured new U.S. patent covering ATR-12, the Company's lead product candidate being developed for Netherton syndrome.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced poster presentation at American Society of Gene and Cell Therapy Annual Meeting (ASGCT) 2026 highlighting ATR-01 preclinical data and the broader potential of Azitra's engineered live biotherapeutic platform.","length":222,"tagName":"p"}]},{"val":[{"type":"text","content":"Priced private placement financing of up to approximately $10.5 million, wi...